| # | Title | Journal | Year | Citations |
|---|
| 1 | Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2019 | 592 |
| 2 | Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2020 | 571 |
| 3 | Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ | Annals of Oncology | 2021 | 101 |
| 4 | Patient frailty predicts worse perioperative outcomes and higher cost after radical cystectomy | Surgical Oncology | 2020 | 39 |
| 5 | Immunotherapy failure in adrenocortical cancer: where next? | Endocrine Connections | 2018 | 39 |
| 6 | Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone | Cancer Treatment Reviews | 2013 | 37 |
| 7 | Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study | Bone | 2017 | 33 |
| 8 | Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma | Oral Oncology | 2021 | 33 |
| 9 | Overview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies | Cancers | 2021 | 30 |
| 10 | Activity and safety of temozolomide in advanced adrenocortical carcinoma patients | European Journal of Endocrinology | 2019 | 30 |
| 11 | Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes | Cancer Treatment Reviews | 2020 | 28 |
| 12 | Contemporary Age-adjusted Incidence and Mortality Rates of Renal Cell Carcinoma: Analysis According to Gender, Race, Stage, Grade, and Histology | European Urology Focus | 2021 | 28 |
| 13 | A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients | Scientific Reports | 2020 | 27 |
| 14 | Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy | JAMA Network Open | 2019 | 26 |
| 15 | The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients | Prostate Cancer and Prostatic Diseases | 2021 | 24 |
| 16 | Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion | ESMO Open | 2020 | 23 |
| 17 | Treatment With 90Y/177Lu-DOTATOC in Patients With Metastatic Adrenocortical Carcinoma Expressing Somatostatin Receptors | Journal of Clinical Endocrinology and Metabolism | 2020 | 22 |
| 18 | Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients | Journal of Geriatric Oncology | 2020 | 21 |
| 19 | The 8th TNM classification for oral squamous cell carcinoma: What is gained, what is lost, and what is missing | Oral Oncology | 2020 | 20 |
| 20 | Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis | Neuroendocrinology | 2021 | 19 |
| 21 | Survival and Complication Rates of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma Treated Exclusively With Targeted Therapy: A Combined Population-based Analysis | Anticancer Research | 2019 | 17 |
| 22 | Malignant tumors of the maxillary sinus: Prognostic impact of neurovascular invasion in a series of 138 patients | Oral Oncology | 2020 | 17 |
| 23 | Gene Expression Profiling of Olfactory Neuroblastoma Helps Identify Prognostic Pathways and Define Potentially Therapeutic Targets | Cancers | 2021 | 17 |
| 24 | The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts | Cancers | 2022 | 17 |
| 25 | A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma | Cells | 2022 | 16 |
| 26 | Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer | Frontiers in Endocrinology | 2021 | 15 |
| 27 | Management of sinonasal adenocarcinomas with anterior skull base extension | Journal of Neuro-Oncology | 2020 | 14 |
| 28 | Renal cell carcinoma incidence rates and trends in young adults aged 20-39 years | Cancer Epidemiology | 2020 | 14 |
| 29 | Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort | European Journal of Cancer | 2021 | 13 |
| 30 | Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects | Cancers | 2020 | 12 |
| 31 | Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study | Prostate Cancer and Prostatic Diseases | 2021 | 11 |
| 32 | Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art? | Expert Opinion on Pharmacotherapy | 2022 | 10 |
| 33 | Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma | Clinical Genitourinary Cancer | 2020 | 9 |
| 34 | Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR) | PLoS ONE | 2019 | 8 |
| 35 | Differences in short-term outcomes between open versus robot-assisted radical cystectomy in frail malnourished patients | European Journal of Surgical Oncology | 2020 | 8 |
| 36 | Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells | Endocrinology | 2022 | 8 |
| 37 | Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events | PLoS ONE | 2019 | 7 |
| 38 | Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma | ESMO Open | 2022 | 7 |
| 39 | Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen | Endocrine | 2022 | 7 |
| 40 | Lung carcinoid tumours: histology and Ki‐67, the eternal rivalry | Histopathology | 2023 | 7 |
| 41 | Bladder cancer incidence rates and trends in young adults aged 20-39 years | Urologic Oncology: Seminars and Original Investigations | 2020 | 5 |
| 42 | Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma | Frontiers in Endocrinology | 2021 | 5 |
| 43 | Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review | Frontiers in Immunology | 2021 | 5 |
| 44 | Assessing Preferences in Patients with Head and Neck Squamous Cell Carcinoma: Phase I and II of Questionnaire Development | Cancers | 2020 | 4 |
| 45 | Non-metastatic ductal adenocarcinoma of the prostate: pattern of care from an uro-oncology multidisciplinary group | World Journal of Urology | 2021 | 4 |
| 46 | Antineoplastic activity of artemisinin in adrenocortical carcinoma | Endocrine | 2019 | 3 |
| 47 | Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network | European Journal of Cancer | 2021 | 3 |
| 48 | Molecular genotyping of adrenocortical carcinoma: a systematic analysis of published literature 2019–2021 | Current Opinion in Oncology | 2022 | 3 |
| 49 | Progression of Vertebral Fractures in Patients with Adrenocortical Carcinoma Undergoing Mitotane Therapy | Journal of Clinical Endocrinology and Metabolism | 2022 | 3 |
| 50 | The observational clinical registry (cohort design) of the European Reference Network on Rare Adult Solid Cancers: The protocol for the rare head and neck cancers | PLoS ONE | 2023 | 3 |
